Charcot-Marie-Tooth (CMT) Disease 1A with Superimposed Inflammatory Polyneuropathy in Children

Abstract

Charcot-Marie-Tooth (CMT) disease is genetically heterogeneous and subdivided into demyelinating (CMT 1) and axonal (CMT 2) types based on neurophysiology findings. CMT1A, the commonest form associated with duplication of the PMP22 segment on chromosome 17p, often arises in childhood but is generally a slowly progressive disease. We report 2 children presenting with clinical features of an acute inflammatory demyelinating polyneuropathy (AIDP) who were subsequently diagnosed with underlying CMT1A. Both children had neurophysiology and histopathology features consistent with CMT1. Immunoglobulin treatment was initiated considering the evidence of superimposed inflammation and appeared to modify disease progression. Our findings indicate that CMT1A predisposes to a superimposed inflammatory neuropathy. Recognition of this association is difficult, particularly in children without clear family history, but of great importance as immunomodulatory treatment may improve outcome. In addition, we postulate that an underlying genetic polyneuropathy should be suspected if the recovery from AIDP is slower than expected, or incomplete.

Key words

Charcot-Marie-Tooth (CMT) - CMT1A - acute inflammatory demyelinating polyneuropathy (AIDP)

References

• 1 Bird SJ, Sladky JT. Corticosteroid-responsive dominantly inherited neuropathy in childhood.  Neurology. 1991;  41 437-439
• 2 Crawford T, Griffin JW. Morphometrical and ultrastructural evaluation of the sural nerve in children with Charcot-Marie-Tooth: Implications for pathogenesis and treatment.  Abstracts, Ann Neurol. 1991;  30 500
• 3 Donaghy M, Sisodiya SM, Kennett R. et al . Steroid responsive polyneuropathy in a family with a novel myelin protein zero mutation.  J Neurol Neurosurg Psychiatry. 2000;  69 799-805
• 4 Dyck PJ, Swanson CJ, Low PA. et al . Prednisone-responsive hereditary motor and sensory neuropathy.  Mayo Clin Proc. 1982;  57 239-246
• 5 Gabriel CM, Gregson NA, Hughes RAC. Anti-PMP22 antibodies in patients with inflammatory neuropathy.  J Neuroimmunol. 2000;  104 139-146
• 6 Gabriel CM, Gregson NA, Wood NW. et al . Immunological study of hereditary motor and sensory neuropathy type 1a.  J Neurol Neurosurg Psychiatry. 2002;  72 230-235
• 7 Ginsberg L, Malik O, Kenton AR. et al . Coexistent hereditary and inflammatory neuropathy.  Brain. 2004;  127 193-202
• 8 Houlden H, King R, Blake J. et al . Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I).  Brain. 2006;  129 421-425
• 9 Malandrini A, Villanova M, Dotti MT. et al . Acute inflammatory neuropathy in Charcot-Marie-Tooth disease.  Neurology. 1999;  52 859-861
• 10 Martini R, V Toyka KV. Immune-mediated components of hereditary demyelinating neuropathies: Lessons from animal models and patients.  The Lancet Neurology. 2004;  3 457-465
• 11 Ritz MF, Lechner-Scott J, Scott RJ. et al . Characterisation of autoantibodies to peripheral myelin protein 22 in patients with hereditary and acquired neuropathies.  J Neuoimmunol. 2000;  104 155-163
• 12 Ryan M, Ouvrier R. Hereditary peripheral neuropathies of childhood.  Current Opinion Neurology. 2005;  18 105-110
• 13 Vital A, Vital C, Lagueny A. et al . Inflammatory demyelination in a patient with CMT1A.  Muscle Nerve. 2003;  28 373-376
• 14 Watanabe M, Yamamoto N, Ohkoshi N. et al . Corticosteroid responsive asymmetric neuropathy with a myelin protein zero gene mutation.  Neurology. 2002;  59 769
• 15 Willis J, Van den Bergh P. Cerebral involvement in children with acute and relapsing inflammatory polyneuropathy.  J Child Neurol. 1988;  3 200-204

Correspondence